KAT2B is an immune infiltration-associated biomarker predicting prognosis and response to immunotherapy in non-small cell lung cancer.
Xue ZhouNing WangYuefeng ZhangHongzhi YuQi WuPublished in: Investigational new drugs (2021)
This is the first comprehensive study to disclose that KAT2B is correlated with immune infiltrates and may serve as a novel biomarker predicting prognosis and response to immunotherapy in NSCLC.